Roche skin cancer drug to get priority review in US
Roche's experimental skin cancer drug vismodegib has been given "priority review" status by U.S. authorities, the Swiss drugmaker said on Wednesday. The news comes hot on the heels of approval in August for Roche's targeted drug Zelboraf for the deadliest form of skin cancer, which came two months ahead of schedule.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063